Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

Next Previous
X
Search
Trial Profile

Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2012 Planned end date changed from 1 Jan 2012 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 10 May 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top